September 27, 2017 / 11:29 AM / a year ago

BRIEF-Acorda Therapeutics announced update on refusal to file letter that it received from U.S. FDA

Sept 27 (Reuters) - Acorda Therapeutics Inc:

* Acorda Therapeutics ‍announced update on refusal to file letter that it received from U.S. FDA regarding its new drug application for Inbrija​

* Says it ‍has engaged in a constructive dialogue with FDA to determine most efficient path forward to resubmitting Inbrija NDA​

* Acorda Therapeutics - ‍based on interactions with FDA, co believes it can resubmit without a type a meeting, and therefore will not request such a meeting​

* Acorda Therapeutics - ‍reiterated that issues raised in RTF are addressable and that FDA has not requested or recommended additional clinical efficacy or safety studies​

* Says it ‍plans to resubmit NDA for ‍Inbrija​ as soon as possible​ Source text: ( Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below